15-Year watch: tracking gene Therapy's lasting impact on blood disorders
NCT ID NCT05145062
Summary
This study is tracking the long-term safety and effectiveness of two gene therapies (BIVV003 and ST-400) for up to 15 years. It follows 8 people who have already received these treatments for severe sickle cell disease or transfusion-dependent beta-thalassemia. The main goal is to see if the therapies remain safe and continue to control the diseases over a very long period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLOOD AND LYMPHATIC DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boston Children's Hospital
Boston, Massachusetts, 02115, United States
-
Children's Healthcare of Atlanta
Atlanta, Georgia, 30329, United States
-
Henry Ford Health System
Detroit, Michigan, 48202, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
UCSF Benioff Children's Hospital
Oakland, California, 94609, United States
-
University of California Davis Health System
Sacramento, California, 95817, United States
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
Conditions
Explore the condition pages connected to this study.